METIS Innovative

Investment decisions are made by the founding partners: Dr. Dimitri Sigounas, Dr. Christopher Kellner, and Brian Sidman. Sigounas and Kellner are practicing academic neurosurgeons who evaluate the clinical merit of target technologies, while Sidman leads capital formation and deal structuring. This dual clinical-operational investment committee model is central to the firm's sourcing and diligence process.

METIS sources through the clinical networks of its physician founders, who encounter neurotechnology innovations through academic medicine, surgical practice, and research collaborations. The firm also leverages its reputation as an early backer of prominent neurotech companies, attracting inbound interest from founders developing brain-computer interfaces, neuromodulation, and neurosurgical devices. No formal scout network or institutional sourcing platform is disclosed.

METIS Innovative is structured as an asset manager and investment firm, not a single family office. While the firm does not publicly disclose its limited partner base, it operates as a private investment vehicle deploying capital raised from external investors alongside the founders. The firm is occasionally described as a 'private equity firm' in structured data, though its investment stage is seed and early-stage venture.

Currently, METIS appears to make only direct equity investments into early-stage neurotechnology and medical device companies. The firm's disclosed portfolio consists entirely of direct company positions. There is no public record of fund-of-fund commitments or co-investment alongside external GPs.

METIS targets seed and early-stage companies. The firm describes its investments as 'promising early stage medical devices and technology in the neurosciences,' and portfolio companies such as Synchron, Proprio, and Fluid Biomed were backed at stages ranging from pre-clinical to early human trials.

METIS focuses exclusively on neuroscience and neurotechnology — specifically medical devices, brain-computer interfaces, and digital health platforms for neurological conditions. The firm does not invest in pharmaceuticals, biotechnology outside the CNS space, or therapeutic areas beyond neurology. No investments have been disclosed in non-neuro health sectors.

The firm does not publicly disclose its limited partner base or the specific source of its investment capital. Co-founder Brian Sidman is described as a 'veteran of capital accrual for investment opportunities,' but the scale, structure, and identity of the firm's funding sources remain undisclosed as of mid-2025.